-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 3, Betta Pharmaceuticals announced that its third-generation EGFR-TKI befortinib mesylate capsule (BPI-D0316) has been accepted by the National Food and Drug Administration (NMPA) for the marketing authorization application, and it is intended for past use Treatment of locally advanced or metastatic non-small cell lung cancer with T790M mutation after EGFR-TKI resistance.
EGFR is a group of cell surface receptors of the epidermal growth factor family with tyrosine kinase activity.
Befortinib mesylate capsule is a third-generation EGFR-TKI developed by Betta Pharmaceuticals for the T790M mutation.
The results of the study showed that the objective response rate (ORR) assessed by the Independent Review Committee (IRC) was 64.
In terms of safety, the incidence of adverse reactions among subjects during the treatment period was 91.
According to the press release, befortinib mesylate is a collaborative project developed by Betta Pharmaceuticals and Yifang Bio.
Betta Pharmaceuticals focuses on the research and development of lung cancer targeted drugs.